Geeta Vemuri serves as Managing Partner at Agent Capital that has raised $52 million for a maiden venture capital fund early 2018.
Prior to Agent Capital, Dr. Vemuri was the Managing Partner of Baxalta Ventures, the corporate venture capital arm of Baxalta, where she led investment decisions for the $200M pool of capital across multiple therapeutic areas of interest to Baxalta.
Prior to Baxalta Ventures, Dr. Vemuri joined Baxter International to establish and lead investments for its corporate venture capital arm. As the Managing Partner of Baxter Ventures, she led the investment decisions for the $200M pool of capital, including direct equity investments and select fund investments. Prior to Baxter, Dr. Vemuri was a Partner at Quaker BioVentures where she previously joined as a Senior Associate. While at Quaker Partners, she was focused on biotech and healthcare investments. Dr. Vemuri has served on the board as voting member or observer of a variety of companies, including Cempra (until its IPO and Dr. Vemuri’s departure in 2011), Covagen (acq. by J&J), Gadeta BV (until departure from Shire in 2016), Naurex (acq. by Allergan), Ocular Therapeutix, Protez Pharmaceuticals (acq. by Novartis), Syntimmune (until departure from Shire in 2016), True North Therapeutics (acq. by Biovertis), and Vitesse Biologics. Dr. Vemuri received a PhD in biochemistry from Indian Institute of Sciences and an MBA from Wharton School of the University of Pennsylvania.
She also served as the Board Member at Aptinyx, as Vice President at Baxter Ventures, as the Board Member at Syntimmune and as a Partner of Quaker BioVentures.
She joined Quaker BioVentures as a Senior Associate in 2003 and was promoted to Partner in 2008. She is a former board member of Protez Pharmaceuticals, which was recently sold to Novartis and is also a current member of the Board of Directors at Argolyn BioSciences, Cellatope, Opsona Therapeutics and Immune Control. She is a Board Observer for Optherion, Regado, Tengion and Tranzyme. Prior to Quaker, Dr. Vemuri was an Associate at Toucan Capital. Dr. Vemuri has also served as an Associate Analyst at Salomon Smith Barney. Earlier in her career, she was a Research Scientist at The Wistar Institute and postdoctoral fellow at Thomas Jefferson University. Dr. Vemuri received her M.S. from Central University in India, her Ph.D. in biochemistry from the Indian Institute of Sciences and her M.B.A. from the Wharton School of the University of Pennsylvania. She currently serves on the Board of Directors of Gliknik and Executive Committee of Southeast BIO and the Advisory Committees of BioAdvance Greenhouse and the Sid Martin Biotechnology Incubator.
Previously: Associate at Toucan Capital, where she was responsible for investments in seed-stage and start-up biotech opportunities. Participated in raising capital and helped start several portfolio companies by identifying technologies from universities. Associate Equity Analyst at SalomonSmithBarney and First Union Securities covering specialty pharmaceuticals and healthcare sectors. Research scientist at The Wistar Institute and postdoctoral fellow at Thomas Jefferson University.
Current Board Responsibilities: Argolyn, Cellatope, and Protez Pharmaceuticals.
Board Observer Responsibilities: Immune Control, Optherion, Regado Biosciences, Tengion, and Tranzyme Pharma
Other: Advisory Committee of the Sid Martin Biotechnology Incubator, Board of Directors and Executive Committee of Southeast BIO, the Advisory Committee of BioAdvance Greenhouse, and the Selection Committee for the "Best Incubator Company of the Year" Awards for companies located in Maryland.
Education: M.S. from Central University in India, Ph.D. in Biochemistry from Indian Institute of Sciences, and M.B.A. from the Wharton School of the University of Pennsylvania.
MEDIA ABOUT GEETA VEMURI